Publicaciones en colaboración con investigadores/as de Erasmus University Medical Center (25)

2024

  1. SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer

    Annals of Oncology, Vol. 35, Núm. 1, pp. 66-76

2023

  1. Predictors of embolism and death in left-sided infective endocarditis: the European Society of Cardiology EURObservational Research Programme European Infective Endocarditis registry

    European Heart Journal, Vol. 44, Núm. 43, pp. 4566-4575

  2. Priorities in Cardio-Oncology Basic and Translational Science: GCOS 2023 Symposium Proceedings: JACC: CardioOncology State-of-the-Art Review

    JACC: CardioOncology, Vol. 5, Núm. 6, pp. 715-731

2022

  1. SLITRK2 variants associated with neurodevelopmental disorders impair excitatory synaptic function and cognition in mice

    Nature Communications, Vol. 13, Núm. 1

2021

  1. Heterozygous ANKRD17 loss-of-function variants cause a syndrome with intellectual disability, speech delay, and dysmorphism

    American Journal of Human Genetics, Vol. 108, Núm. 6, pp. 1138-1150

  2. Protecting older patients with cardiovascular diseases from COVID-19 complications using current medications

    European Geriatric Medicine, Vol. 12, Núm. 4, pp. 725-739

  3. The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group

    npj Breast Cancer, Vol. 7, Núm. 1

2020

  1. Diagnostic and predictive value of Doppler ultrasound for evaluation of the brain circulation in preterm infants: a systematic review

    Pediatric Research, Vol. 87, pp. 50-58

  2. Partial Loss of USP9X Function Leads to a Male Neurodevelopmental and Behavioral Disorder Converging on Transforming Growth Factor β Signaling

    Biological Psychiatry, Vol. 87, Núm. 2, pp. 100-112

  3. Toward a geriatric approach to patients with advanced age and cardiovascular diseases: position statement of the EuGMS Special Interest Group on Cardiovascular Medicine

    European Geriatric Medicine, Vol. 11, Núm. 1, pp. 179-184

2019

  1. Effects of ABO matching of platelet transfusions in critically III children

    Pediatric Critical Care Medicine, Vol. 20, Núm. 2, pp. E61-E69

2018

  1. Platelet Transfusion Practices in Critically Ill Children

    Critical Care Medicine, Vol. 46, Núm. 8, pp. 1309-1317

  2. Relationship between episodic memory and volume of the brain regions of two functional cortical memory systems in multiple sclerosis

    Journal of Neurology, Vol. 265, Núm. 10, pp. 2182-2189

2017

  1. Influence of the amount of myocardium subtended to a coronary stenosis on the index of microcirculatory resistance. Implications for the invasive assessment of microcirculatory function in ischaemic heart disease

    EuroIntervention, Vol. 13, Núm. 8, pp. 944-952

  2. Stem cell-like transcriptional reprogramming mediates metastatic resistance to mTOR inhibition

    Oncogene, Vol. 36, Núm. 19, pp. 2737-2749

2015

  1. Genome-wide significant association with seven novel multiple sclerosis risk loci

    Journal of Medical Genetics, Vol. 52, Núm. 12, pp. 848-855

2014

  1. Opportunistic infections and AIDS malignancies early after initiating combination antiretroviral therapy in high-income countries

    AIDS, Vol. 28, Núm. 16, pp. 2461-2473

2013

  1. Dutasteride treatment over 2 years delays prostate-specific antigen progression in patients with biochemical failure after radical therapy for prostate cancer: Results from the randomised, placebo-controlled avodart after radical therapy for Prostate Cancer Study (ARTS)

    European Urology, Vol. 63, Núm. 5, pp. 779-787

  2. MANBA, CXCR5, SOX8, RPS6KB1 and ZBTB46 are genetic risk loci for multiple sclerosis

    Brain, Vol. 136, Núm. 6, pp. 1778-1782

  3. Reply from authors re: Behfar Ehdaie, Karim A. Touijer. 5-Alpha reductase inhibitors in prostate cancer: From clinical trials to clinical practice. Eur Urol 2013;63:788-9: 5-Alpha reductase inhibitors in prostate cancer

    European Urology